LobbyingAmo Pharma lobbying by quarter
Amo Pharma's latest lobbying report covers Q2 2026, at $50K. The four quarters Q4 2025–Q3 2026 total $150K. Its first report covers Q3 2025; the issues it reports most are Health Issues.
Amo Pharma
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $150K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q3 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2025 | $0 | 1 |
| Q4 2025 | $50K | 1 |
| Q1 2026 | $50K | 1 |
| Q2 2026 | $50K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$150K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
Firms it paid
| Firm | ||
|---|---|---|
| Burrell International Group | $150K | 4 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/19for Q2 | Burrell International Group | $50K |
| 04/17for Q1 | Burrell International Group | $50K |
| 01/14for Q4 2025 | Burrell International Group | $50K |
| 25/10/20for Q3 2025 | Burrell International Group | Under $5,000 |
| 25/10/19for Q3 2025 | Burrell International Group | Under $5,000 |